This week’s edition urges you to get more sleep, watch the drinking if kids are in your plans. Also, results from SCOPE-1, and perhaps something to think about if you’re a practitioner prescribing ibrutinib.
Middle-age adults, particularly those with hypertension, type 2 diabetes, obesity, and other risk factors, should be getting at least six hours of sleep per night to keep down an increased risk for heart disease, stroke, and even cancer death. A new study in the Journal of the American Heart Association looking over 1,600 middle-aged adults suggested that the risk for cardiovascular- and cerebrovascular-linked death was significantly increased in participants who slept less than six hours per night. “Clinicians should become aware that the risk of all‐cause and cancer mortality associated with hypertension, diabetes mellitus, heart disease, or stroke is greater in patients with objective short sleep duration, a potentially modifiable risk factor,” the researchers wrote.
Mothers- and especially fathers-to-be should refrain from consuming alcohol for up to six months prior to attempting conception, due to an increased risk for congenital heart disease for any offspring, a new study in the European Journal of Preventive Cardiology suggests. The researchers for this observational study, while not discriminating as to the type of alcohol, nevertheless reported that alcohol consumption (and especially heavier consumption) by both fathers and mothers prior to conception was associated with an increased risk in congenital heart disease offspring.
A drug that has been described as “revolutionizing” treatment for several B-cell malignancies has also been linked to increased risk for some adverse cardiovascular events, according to a new analysis published in the Journal of the American College of Cardiology. The study authors pulled form the VigiBase and preformed statistical analyses to identify relationships between deaths linked with cardiovascular adverse drug reactions and those that occurred in patients taking with ibrutinib. “Severe and occasionally fatal cardiac events occur in patients exposed to ibrutinib,” they wrote. “These events should be considered in patient care and in clinical trial designs.”
Fresh from TCT 2019 and published in The Lancet, this study of over 700 patients compared the self-expanding ACURATE neo transcatheter aortic valve to an industry standard, balloon-expandable SAPIEN 3 aortic valve. “Transcatheter aortic valve replacement with the self-expanding ACURATE neo did not meet non-inferiority compared to the balloon-expandable SAPIEN 3 device in terms of early safety and clinical efficacy outcomes”